Myriad Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Myriad Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-45,000	Closed	-$2.21M	–	170
2021 Q3	$2.21M	Buy	+45,000	New	+$2.2M	0.23%	77
2021 Q2	–	Sell	-32,000	Closed	-$1.14M	–	153
2021 Q1	$1.14M	Buy	+32,000	New	+$1.06M	0.12%	86

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Myriad Asset Management's MRVI Position: Q4 2021 in Review

Myriad Asset Management sold out of Maravai LifeSciences (MRVI) in Q4 2021, closing a stake of 45,000 shares — an estimated $2.21M sold.

Myriad Asset Management first reported a position in MRVI in Q1 2021 and held it in 2 quarters. The position peaked at $2.21M in Q3 2021. 229 funds tracked by Wall St. Rank hold MRVI as of Q4 2021.

Myriad Asset Management reported no remaining Maravai LifeSciences position as of Q4 2021 after selling out during the quarter.
Myriad Asset Management sold 45,000 Maravai LifeSciences shares in Q4 2021, an estimated $2.21M.
Myriad Asset Management first reported a position in Maravai LifeSciences in Q1 2021 and held it in 2 quarters.
Myriad Asset Management's Maravai LifeSciences position peaked at $2.21M in Q3 2021.
229 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2021.

Based on Myriad Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.